vivoVerse (formerly operating as Newormics) is excited to announce it has been awarded a $2.25M Phase II SBIR grant from the National Institutes of Health/National Institute of Mental Health (NIMH) Read more about vivoVerse awarded SBIR Phase II grant from the NIMH[…]
Dear Customers, Colleagues, and Collaborators: At Newormics, we recognize that combating the spread of this new virus requires a global community effort. As we navigate this uncharted landscape together with Read more about COVID-19 UPDATE[…]
Early larval stages of C. elegans (L1 to L3 and Dauer) have always been among the hardest to immobilize and image successfully, due to their tiny size and difficulties with Read more about Newormics launches new vivoChips for early stage worms[…]
The research of Newormics is featured in a special report in the July 2019 issue of DDNews in an article titled “Phenotypic finery: Microscopy meets the molecular in the search Read more about DDNews features Newormics in their latest issue in a special report on drug screening[…]
Newormics is exhibiting at the 2019 UK C. elegans meeting at Imperial College London on September 16th. Come meet us and view our latest imaging solutions there. We will also Read more about Newormics at the 2019 UK C. elegans meeting[…]
Newormics was awarded an SBIR Phase I grant from the National Institute of Environmental Health Sciences (NIEHS) for the project “A Large-Scale Microfluidics Imaging Platform for High-Throughput Toxicity Testing using Read more about Newormics awarded an SBIR Phase I grant from the NIEHS[…]
Newormics is exhibiting at the 22nd International C. elegans Conference at UCLA, Los Angeles from 20th June – 24th June. Come and meet the team here at our booth.
Newormics was selected for the NIH I-Corps April-June 2019 cohort. Over the course of the I-Corps program, the team had conversations with over 100 stakeholders in the field. This helped Read more about Newormics selected for the NIH I-Corps[…]
Newormics was awarded an SBIR Phase I grant from the National Institute of Mental Health (NIMH) for the project “A multi-well plate format microfluidic immobilization chip for high-content imaging of Read more about Newormics awarded SBIR Phase I grant from the NIMH[…]
Dr. Sudip Mondal has a Ph.D. in Physics and several years of postdoctoral research experience in neuroscience and microfluidics-based screening tools. He has developed several technologies that have translated to the market. One of his recent works at The University of Texas at Austin involved a high-throughput screening platform with C. elegans model systems, which is commercialized by vivoVerse. As a Director of Science, Sudip is responsible for developing new technologies and innovative assays to increase the vivoVerse product & service portfolio.
Evan Hegarty, co-founder, received his M.S. in Mechanical Engineering at The University of Texas at Austin while developing the technology and IP that lead to the launch of Newormics, LLC, now vivoVerse. As the Director of Manufacturing and Product development, and Principal Investigator of NIH SBIR grants at vivoVerse, Evan is responsible for development of all chip and system designs, creating production schedules, optimizing production methods, managing team members, identifying customer needs, developing future products, and reinforcing GLP and GMP.
A professor with dual appointments in Mechanical Engineering and Biomedical Engineering at The University of Texas at Austin, Dr Ben-Yakar’s research focuses on the creation of imaging technologies and novel laser surgery with high precision. Educated at Stanford and the Technion in Israel, with post-doctoral study at Harvard, and using her NIH Director’s Transformative Research Award, Dr Ben-Yakar began the research that has culminated in the launch of vivoVerse (formerly Newormics)